Article

O'Brien CA, Pollett A, Gallinger S, Dick JE.. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445: 106-110

Division of Cell and Molecular Biology, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
Nature (Impact Factor: 42.35). 02/2007; 445(7123):106-10. DOI: 10.1038/nature05372
Source: PubMed

ABSTRACT Colon cancer is one of the best-understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death, indicating that some of its cancer cells are not eradicated by current therapies. What has yet to be established is whether every colon cancer cell possesses the potential to initiate and sustain tumour growth, or whether the tumour is hierarchically organized so that only a subset of cells--cancer stem cells--possess such potential. Here we use renal capsule transplantation in immunodeficient NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). Purification experiments established that all CC-ICs were CD133+; the CD133- cells that comprised the majority of the tumour were unable to initiate tumour growth. We calculated by limiting dilution analysis that there was one CC-IC in 5.7 x 10(4) unfractionated tumour cells, whereas there was one CC-IC in 262 CD133+ cells, representing >200-fold enrichment. CC-ICs within the CD133+ population were able to maintain themselves as well as differentiate and re-establish tumour heterogeneity upon serial transplantation. The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem cells.

Download full-text

Full-text

Available from: Aaron Pollett, Sep 04, 2015
2 Followers
 · 
468 Views
 · 
901 Downloads
    • "In fact, EpCAM overexpression was appointed as an indicator of increased stage and grade, and poor prognosis in bladder cancer [125] [126]. In addition, EpCAM has also been identified as a marker for cancer-initiating stem cells, making it an interesting target for cancer antibody-based therapeutic strategies [127] [128]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer is the most common malignancy of the urinary tract, presents the highest recurrence rate among solid tumors and is the second leading cause of death in genitourinary cancers. Despite recent advances in understanding of pathophysiology of the disease, the management of bladder cancer patients remains a clinically challenging problem. Particularly, bladder tumors invading the muscularis propria and disseminated disease are often not responsive to currently available therapeutic approaches, which include surgery and conventional chemotherapy. Antibody-based therapeutic strategies have become an established treatment option for over a decade in several types of cancer. However, bladder cancer has remained mostly an "orphan disease" regarding the introduction of these novel therapeutics, which has been translated in few improvements in patients overall survival. In order to shift this paradigm, several clinical studies involving antibody-based therapeutic strategies targeting the most prominent bladder cancer-related biomolecular pathways and immunological mediators are ongoing. This systematic review explores antibody-based therapeutics for bladder cancer undergoing clinical trial and discusses the future perspectives in this field, envisaging the development of more effective guided therapeutics. Copyright © 2015. Published by Elsevier B.V.
    Journal of Controlled Release 09/2015; 214:40–61. DOI:10.1016/j.jconrel.2015.07.002 · 7.26 Impact Factor
    • "Most research over the past decade has been placed into routinely separating and isolating subsets of tumorigenic cells or cancer stem cells (CSCs), taken from solid tumors, that had one or a couple of distinct cellular markers, such as membrane antigens representing their cluster of differentiation (CD), that separate them from non-tumorigenic cells (Al-Hajj et al., 2003; Bonnet and Dick, 1997; Haraguchi et al., 2006; Ho et al., 2007; Lapidot et al., 1994; O'Brien et al., 2007; Olempska et al., 2007; Prince et al., 2007; Ricci-Vitiani et al., 2007; Schatton et al., 2008; Seigel et al., 2007; Singh et al., 2003; Singh et al., 2004; Wang et al., 2007; Zen et al., 2007). CSCs are similar to normal stem cells in self-renewal, unlimited proliferative potential, infrequent or slow replication cycles, and resistance to toxic xenobiotics as well as radiation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Utilization of environmental stimuli for growth is the main factor contributing to the evolution of prokaryotes and eukaryotes, independently and mutualistically. Epigenetics describes an organism's ability to vary expression of certain genes based on their environmental stimuli. The diverse degree of dose-dependent responses based on their variances in expressed genetic profiles makes it difficult to ascertain whether hormesis or oncogenesis has or is occurring. In the medical field this is shown where survival curves used in determining radiotherapeutic doses have substantial uncertainties, some as large as 50% (Barendsen, 1990). Many in-vitro radiobiological studies have been limited by not taking into consideration the innate presence of microbes in biological systems, which have either grown symbiotically or pathogenically. Present in-vitro studies neglect to take into consideration the varied responses that commensal and opportunistic pathogens will have when exposed to the same stimuli and how such responses could act as stimuli for their macro/microenvironment. As a result many theories such as radiation carcinogenesis explain microscopic events but fail to describe macroscopic events (Cohen, 1995). As such, this review shows how microorganisms have the ability to perturb risks of cancer and enhance hormesis after irradiation. It will also look at bacterial significance in the microenvironment of the tumor before and during treatment. In addition, bacterial systemic communication after irradiation and the host's immune responses to infection could explain many of the phenomena associated with bystander effects. Therefore, the present literature review considers the paradigms of hormesis and oncogenesis in order to find a rationale that ties them all together. This relationship was thus characterized to be the microbiome. Copyright © 2015 Elsevier Inc. All rights reserved.
    Environmental Research 07/2015; 142:239-256. DOI:10.1016/j.envres.2015.06.026 · 3.95 Impact Factor
  • Source
    • "Both colorectal and mammary carcinoma are leading causes of cancer-related mortality worldwide [1e3]. Colorectal carcinoma causes approximately 50,000 deaths in the United States and 655,000 deaths throughout the world per year [4] [5]. Breast cancer is the most common malignancy in women, with one in nine women developing breast cancer during their lifetime [6] and cancer death with more than a million newly diagnosed cases annually worldwide [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: As a synergistic drug combination, doxorubicin-loaded cisplatin crosslinked polysaccharide-based nanoparticles (Dex-SA-DOX-CDDP) have demonstrated enhanced antitumor efficacy and reduced systemic toxicity via optimized biodistribution, controlled drug release, prolonged blood circulation, and improved tolerability, compared to the non-crosslinked nanoparticles or free doxorubicin. Herein, we apply the Dex-SA-DOX-CDDP nanoparticles as an efficient antitumor agent to treat colorectal and breast tumors in three different in vivo models, i.e. subcutaneously implanted colorectal carcinoma, dimethylhydrazine-induced autochthonous colorectal carcinoma, and metastatic mammary carcinoma, which more closely simulate the natural milieu of the original tumor with intact pathological and immunological responses. Based on the properties of this combination in higher tumor accumulation and penetrating efficiency, the Dex-SA-DOX-CDDP nanoparticles significantly decreased the tumor sizes in CT26 cell line xenograft tumors compared to control. In addition, the affected animals' lifespan was significantly extended after the Dex-SA-DOX-CDDP treatment, in the autochthonous colon cancer model. Moreover, with the aid of iRGD, Dex-SA-DOX-CDDP could effectively block primary tumor growth and prevent the metastasis of 4T1 murine mammary carcinoma. In conclusion, Dex-SA-DOX-CDDP nanoparticles remarkably inhibit growth of colorectal carcinoma and metastasis of mammary carcinoma in vivo, which provides potential application as a safe and efficient antitumor agent in treatment of these cancers. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Biomaterials 05/2015; 51. DOI:10.1016/j.biomaterials.2015.02.002 · 8.31 Impact Factor
Show more